Anti-neoplastic urinary protein
Alternative Names: ANUP; Human anti-neoplastic urinary proteinLatest Information Update: 17 Jan 2011
Price :
$50 *
At a glance
- Originator Antitumor Research Products
- Developer TranXenoGen
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Jan 2011 No development reported - Preclinical for Cancer in USA (unspecified route)
- 19 Feb 2007 Preclinical development is ongoing
- 18 Nov 2003 ANUP peptides are available for licensing